A pharmacological inhibitor of NLRP3 inflammasome prevents non-alcoholic fatty liver disease in a mouse model induced by high fat diet

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Yang, Gabsik ^a   Lee, Hye Eun ^a   Lee, Joo Young ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CRYOPYRIN; ENZYME INHIBITOR; INFLAMMASOME; ISOTHIOCYANIC ACID DERIVATIVE; NLRP3 PROTEIN, MOUSE; SULFORAFAN;

ADVERSE EFFECTS; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DISEASE MODEL; LIPID DIET; LIVER; LIVER FUNCTION TEST; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE; ORAL DRUG ADMINISTRATION; PATHOLOGY; PHYSIOLOGY; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANIMALS; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; INFLAMMASOMES; ISOTHIOCYANATES; LIVER; LIVER FUNCTION TESTS; MALE; MICE, INBRED C57BL; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; NON-ALCOHOLIC FATTY LIVER DISEASE; TREATMENT OUTCOME;

EID: 84963795296     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep24399     Document Type: Article

References (32)

1. Bechmann, L. P. et al. The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol 56, 952-964 (2012).
2. Wree, A., Kahraman, A., Gerken, G. & Canbay, A. Obesity affects the liver-the link between adipocytes and hepatocytes. Digestion 83, 124-133 (2010).
3. Miura, K. et al. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology 139, 323-334 e327 (2010).
4. Petrasek, J. et al. IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice. J Clin Invest 122, 3476-3489 (2012).
5. Petrasek, J., Dolganiuc, A., Csak, T., Kurt-Jones, E. A. & Szabo, G. Type I interferons protect from Toll-like receptor 9-Associated liver injury and regulate IL-1 receptor antagonist in mice. Gastroenterology 140, 697-708 e694 (2011).
6. Martinon, F., Burns, K. & Tschopp, J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-? . Mol Cell 10, 417-426 (2002).
7. Szabo, G. & Petrasek, J. Inflammasome activation and function in liver disease. Nat Rev Gastroenterol Hepatol 12, 387-400 (2015).
8. Szabo, G. & Csak, T. Inflammasomes in liver diseases. J Hepatol 57, 642-654 (2012).
9. Dixon, L. J., Berk, M., Thapaliya, S., Papouchado, B. G. & Feldstein, A. E. Caspase-1-mediated regulation of fibrogenesis in dietinduced steatohepatitis. Lab Invest 92, 713-723 (2012).
10. Petrasek, J. et al. IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice. J Clin Invest 122, 3476-3489 (2012).
11. Dixon, L. J., Flask, C. A., Papouchado, B. G., Feldstein, A. E. & Nagy, L. E. Caspase-1 as a Central Regulator of High Fat Diet-Induced Non-Alcoholic Steatohepatitis. PLos ONE 8, e56100 (2013).
12. Csak, T. et al. Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology 54, 133-144 (2011).
13. Wen, H. et al. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat Immunol 12, 408-415 (2011).
14. Tavares De Almeida, I., Cortez-Pinto, H., Fidalgo, G., Rodrigues, D. & Camilo, M. E. Plasma total and free fatty acids composition in human non-Alcoholic steatohepatitis. Clin Nutr 21, 219-223 (2002).
15. Choi, K. M. et al. Sulforaphane attenuates obesity by inhibiting adipogenesis and activating the AMPK pathway in obese mice. J Nutr Biochem 25, 201-207 (2014).
16. Zhou, R., Lin, J. & Wu, D. Sulforaphane induces Nrf2 and protects against CYP2E1-dependent binge alcohol-induced liver steatosis. Biochim Biophys Acta 1840, 209-218 (2014).
17. Zhou, R., Yazdi, A. S., Menu, P. & Tschopp, J. A role for mitochondria in NLRP3 inflammasome activation. Nature 469, 221-225 (2011).
18. Lim, Y. M. et al. Systemic autophagy insufficiency compromises adaptation to metabolic stress and facilitates progression from obesity to diabetes. Nat Commun 5, 4934 (2014).
19. Schroder, K. & Tschopp, J. The Inflammasomes. Cell 140, 821-832 (2010).
20. Nakahira, K. et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat Immunol 12, 222-230 (2011).
21. Ilyas, G. et al. Macrophage autophagy limits acute toxic liver injury in mice through down regulation of interleukin-1beta. J Hepatol 64, 118-127 (2016).
22. Lee, H. M. et al. Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes. Diabetes 62, 194-204 (2013).
23. Misawa, T. et al. Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome. Nat Immunol 14, 454-460 (2013).
24. Ayonrinde, O. T. et al. Gender-specific differences in adipose distribution and adipocytokines influence adolescent nonalcoholic fatty liver disease. Hepatology 53, 800-809 (2011).
25. Tarantino, G., Savastano, S. & Colao, A. Hepatic steatosis, low-grade chronic inflammation and hormone/growth factor/adipokine imbalance. World Journal of Gastroenterology: WJG 16, 4773-4783 (2010).
26. Younossi, Z. M. et al. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine (Baltimore) 91, 319-327 (2012).
27. Carulli, L., Lonardo, A., Lombardini, S., Marchesini, G. & Loria, P. Gender, fatty liver and GGT. Hepatology 44, 278-279 (2006).
28. McKenzie, J. et al. Effects of HRT on liver enzyme levels in women with type 2 diabetes: a randomized placebo-controlled trial. Clin Endocrinol (Oxf) 65, 40-44 (2006).
29. Zhang, W. et al. PCB 126 and other dioxin-like PCBs specifically suppress hepatic PEPCK expression via the aryl hydrocarbon receptor. PLos One 7, e37103 (2012).
30. Jeong, E. et al. PPAR? deficiency disrupts hypoxia-mediated tumorigenic potential of colon cancer cells. Mol Carcinog 53, 926-937 (2014).
31. Kleiner, D. E. et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313-1321 (2005).
32. Folch, J., Lees, M. & Sloane Stanley, G. H. A simple method for the isolation and purification of total lipides from animal tissues. The Journal of biological chemistry 226, 497-509 (1957).